At the heart of PRIME-ROSE is the ambition to bring together expertise across Europe and make precision cancer treatment more accessible to patients. Research exchanges play an important role in this, creating opportunities for shared learning and closer collaboration between countries.

Over the past four months, medical student at the University of Copenhagen, Tine Østergaard, has been part of this effort through a research stay at the Dutch DRUP trial, as part of her work within the Danish ProTarget study. The research stay was made possible through a collaboration between the Phase 1 Unit, Department of Oncology at Rigshospitalet in Copenhagen, and partners in the Netherlands, including the Department of Medical Oncology at Leiden University Medical Center and the Emile Voest Group at the Netherlands Cancer Institute.

During her stay, she has focused on her master’s thesis, investigating multi-omic markers associated with clinical outcomes in patients with BRAF V600E-mutated solid tumours treated with BRAF/MEK inhibitors beyond standard indications, of which results will be published later this year.

Her project contributes to an emerging basis for cross-border analyses of molecular cohorts, helping to bridge datasets and bring us closer to a more integrated European approach to precision oncology.

This research stay with exchange of knowledge and experience highlights how collaboration in PRIME-ROSE empowers the next generation of researchers working towards more precise, equitable cancer care for all European patients.

‍